- FUNGICIDAL OXADIAZOLES
-
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein R1, Z1, W, Z2 and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.
- -
-
Page/Page column 47
(2019/01/22)
-
- 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTORS
-
The present invention provides compounds of Formula (I), as selective S1 P1 inhibitors, as well as their use for treating multiple sclerosis and other diseases.
- -
-
Page/Page column 92
(2012/02/01)
-
- SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS
-
Disclosed are compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is formula (II) Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
- -
-
Page/Page column 184
(2011/02/24)
-
- AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS
-
The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
- -
-
Page/Page column 17
(2010/04/30)
-
- NOVEL PYRIMIDINE DERIVATIVES
-
The invention relates to novel pyrimidine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII) or Formula (IX)
- -
-
Page/Page column 18
(2010/09/18)
-
- THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1
-
The invention relates to novel thiophene derivatives (1), their preparation and their use as pharmaceutically active compounds.Said compounds particularly act as immunomodulating agents. Formula (I).
- -
-
Page/Page column 16; 17
(2010/11/03)
-
- PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS
-
The present invention relates to pyrazole oxadiazoles derivatives of Formula (I), and their use for treating multiple sclerosis and other diseases. Wherein R1, R2 and R3 are as defined in the description.
- -
-
Page/Page column 89
(2010/12/29)
-
- TRIAZOLE OXADIAZOLES DERIVATIVES
-
The invention relates to compounds of formula (I), wherein R1, R2, Ra, Rb, X have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
- -
-
Page/Page column 120
(2009/07/25)
-
- AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS
-
The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
- -
-
Page/Page column 42
(2008/12/07)
-
- Design and biological evaluation of non-peptide analogues of omega-conotoxin MVIIA
-
Omega-conotoxin MVIIA, a highly potent antagonist of the N-type voltage sensitive calcium channel, has shown utility in several models of pain and ischemia. We report a series of three alkylphenyl ether based analogues which mimic three key amino acids of the toxin. Two of the compounds have been found to exhibit IC50 values of 2.7 and 3.3 μM at the human N-type voltage sensitive calcium channel. (C) 2000 Elsevier Science Ltd. All rights reserved.
- Menzler, Stefan,Bikker, Jack A.,Suman-Chauhan, Nirmala,Horwell, David C.
-
p. 345 - 347
(2007/10/03)
-
- 3-(piperazinylpropyl)indoles: Selective, orally bioavailable h5-HT(1D) receptor agonists as potential antimigraine agents
-
Clinically effective antimigraine drugs such as Sumatriptan have similar affinity at h5-HT(1D) and h5-HT(1B) receptors. In the search for a h5- HT(1D)-selective agonist as an antimigraine agent, a novel series of 3- (propylpiperazinyl)indoles have been sy
- Chambers, Mark S.,Street, Leslie J.,Goodacre, Simon,Hobbs, Sarah C.,Hunt, Peter,Jelley, Richard A.,Matassa, Victor G.,Reeve, Austin J.,Sternfeld, Francine,Beer, Margaret S.,Stanton, Josephine A.,Rathbone, Denise,Watt, Alan P.,MacLeod, Angus M.
-
p. 691 - 705
(2007/10/03)
-
- Synthesis of a non-peptide analogue of omega-conotoxin MVIIA
-
An efficient synthesis of an alkylphenyl ether based peptidomimetic is described. The compound mimics three key amino acids of omega-conotoxin MVIIA from the cone shell Conus magus and may provide an entry to the design of low molecular weight antagonists of N-type neuronal calcium channels.
- Menzler, Stefan,Bikker, Jack A.,Horwell, David C.
-
p. 7619 - 7622
(2007/10/03)
-